 Apellis Pharmaceuticals Inc NASDAQ: APLS shares are trading higher by 8.6 at 43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy. Apellis Pharmaceuticals says, at month 18,. 